Medicare billing address
CMS Medicare provider billing file
3838 S 700 E Ste 100Salt Lake City, UT 84106
CMS public data · NPI 1144663493
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Robert A Havard, M.D.
Specialty
Credential
M.D.
NPI
1144663493
Primary source state
UT
Data retrieval date
July 27, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Robert A Havard, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
3838 S 700 E Ste 100CMS Doctors & Clinicians file
3838 S 700In the 2024 CMS provider billing file, this NPI had 366 Medicare beneficiaries and 95,758 total services. The average beneficiary age was 75, and the average HCC risk score was 1.9.
Total Medicare allowed amount
$1,921,621.03
Total Medicare payment amount
$1,528,500.44
Medicare beneficiaries
366
Total services
95,758
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hypertension
68%
CMS beneficiary-panel share
Hyperlipidemia
58%
CMS beneficiary-panel share
Diabetes
34%
CMS beneficiary-panel share
Chronic kidney disease
32%
CMS beneficiary-panel share
Ischemic heart disease
27%
CMS beneficiary-panel share
Mood disorders
27%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 14,250 | $1.09 |
| Injection, aprepitant, 1 mg | 10,270 | $1.63 |
| Injection, granisetron, extended-release, 0.1 mg | 5,500 | $5.46 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,140 | $0.13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,340 | $0.11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 722 | $7.57 |
| Blood test, comprehensive group of blood chemicals | 599 | $10.29 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 441 | $121.22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 233 | $25.75 |
| Injection of drug or substance under skin or into muscle | 220 | $13.35 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1144663493. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Anastrozole | Anastrozole | 118 | 343.1 | $2,101.51 |
| 2 | Hydroxyurea | Hydroxyurea | 87 | 142.8 | $1,567.71 |
| 3 | Tamoxifen Citrate | Tamoxifen Citrate | 66 | 173.7 | $2,493.47 |
| 4 | Xarelto | Rivaroxaban | 37 | 55 | $32,674.30 |
| 5 | Prednisone | Prednisone | 33 | 37.1 | $147.85 |
| 6 | Brukinsa | Zanubrutinib | 31 | 31 | $448,220.88 |
| 7 | Acyclovir | Acyclovir | 29 | 31 | $215.36 |
| 8 | Imbruvica | Ibrutinib | 28 | 28 | $429,697.16 |
| 9 | Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | 27 | $381.24 |
| 10 | Exemestane | Exemestane | 25 | 43 | $1,683.21 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
2013
Group/practice field
Utah Cancer Specialists Pc
Telehealth reported
Not reported
Secondary specialty fields reported by CMS: Internal Medicine.
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.